Scarica l'app Stockscreener
0.2485
2.05%
0.005
Pre-mercato:
.25
0.0015
+0.60%
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Cellectar Biosciences (NASDAQ:CLRB) Coverage Initiated at StockNews.com - Defense World
Barclays PLC Trims Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (STU:NV4) Enterprise Value : €-9.79 Mil (As of Jan. 19, 2025) - GuruFocus.com
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Cellectar Biosciences (FRA:NV4) Gross Margin % : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Oppenheimer keeps Perform rating on Cellectar Biosciences stock on recent update - Investing.com Canada
Cellectar Biosciences (NASDAQ:CLRB) Earns Sell Rating from Analysts at StockNews.com - Defense World
Cellectar Biosciences to Highlight 2025 Strategic - GlobeNewswire
Cellectar's Cancer Drug Iopofosine Achieves Remarkable 83.6% Response Rate in Phase 2 Trial - StockTitan
S&P Midcap 400 (IDX) QuotePress Release - The Globe and Mail
S&P Smallcap 600 (IQY) QuotePress Release - The Globe and Mail
Barclays PLC Has $258,000 Holdings in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar stock plunges 50% post-market on restructuring news - MSN
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by Analysts at StockNews.com - Defense World
Wall Street’s top 5 stocks with the biggest upside in 2025Finbold - Finbold - Finance in Bold
Is Now The Time To Buy Cellectar Biosciences Inc (NASDAQ: CLRB) Stock? - Stocks Register
Neuroblastoma Therapeutic Market: Analyzing the Impact of High - openPR
Oppenheimer Downgrades Cellectar Biosciences (CLRB) - MSN
Roth Capital Has Optimistic Outlook of CLRB Q1 Earnings - Defense World
Cellectar Biosciences Implements Workforce Reduction Plan to Enhance Operational Efficiency - Defense World
Cellectar Biosciences (FRA:NV4) 10-Year Sharpe Ratio : -0.19 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Sortino Ratio : -0.47 (As of Dec. 12, 2024) - GuruFocus.com
Cellectar Biosci stock hits 52-week low at $0.27 amid sharp decline - Investing.com
Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut - MarketWatch
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options - Benzinga
Cellectar Biosciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar stock plunges 50% post-market on restructuring news (NASDAQ:CLRB) - Seeking Alpha
CLRBCellectar Biosciences INC NEW Latest Stock News & Market Updates - StockTitan
Cellectar refocuses on solid tumor radiotherapies - Investing.com
Cellectar Biosciences Provides Strategic Update on Clinical - GlobeNewswire
Cellectar Shifts Strategy After FDA Feedback, Cuts 60% Workforce to Advance Cancer Pipeline - StockTitan
Waldenstrom Macroglobulinemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp - Barchart
Waldenstrom Macroglobulinemia Market Growth to Accelerate - openPR
Cellectar Biosci stock hits 52-week low at $1.38 By Investing.com - Investing.com Canada
Cellectar Biosci stock hits 52-week low at $1.38 - Investing.com
Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target - Quantisnow
This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? - AOL
Cellectar Biosciences (STU:NV4) Forward Dividend Yield % : 0.00% (As of Dec. 01, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Volatility : 73.35% (As of Nov. 29, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Total Stockholders Equity : €13.66 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) PE Ratio : At Loss (As of Nov. 28, 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Other Long Term Assets : €0.03 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Current Accrued Expense : €7.48 Mil (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (STU:NV4) Quick Ratio : 1.77 (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) 3-Year Book Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) Margin of Safety % (DCF FCF Based) : N/A (As of Nov. 26, 2024) - GuruFocus.com
CLRB (Cellectar Biosciences) EPS without NRI : $-2.17 (TTM As of Sep. 2024) - GuruFocus.com
12,500 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Purchased by Oppenheimer & Co. Inc. - Defense World
Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
Roth Capital Analysts Decrease Earnings Estimates for CLRB - Defense World
Oppenheimer Lowers Cellectar Biosciences (NASDAQ:CLRB) Price Target to $12.00 - Defense World
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Cellectar Signs Critical Radioisotope Supply Deal for Cancer Drug Development | CLRB Stock News - StockTitan
Roth Capital Has Bearish Forecast for CLRB FY2024 Earnings - MarketBeat
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):